NCT06120556View on ClinicalTrials.gov

Efficacy of Glucagon-like Peptide-1 Receptor Agonists According to Type 2 Diabetes Subtypes

CompletedOBSERVATIONAL
Enrollment

130

Participants

Timeline

Start Date

June 10, 2023

Primary Completion Date

October 31, 2023

Study Completion Date

October 31, 2023

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

GLP-1 receptor agonist

Patients initiating a GLP-1 receptor agonist (i.e. liraglutide, dulaglutide, semaglutide) will be included in the study.

Trial Locations (1)

70124

Azienda Ospedaliero-Universitaria Policlinico Bari, Bari

All Listed Sponsors
lead

Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari

OTHER

NCT06120556 - Efficacy of Glucagon-like Peptide-1 Receptor Agonists According to Type 2 Diabetes Subtypes | Biotech Hunter | Biotech Hunter